10x Genomics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
10x Genomics, Inc. (TXG) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $10.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-13
- 10x Genomics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $10.70M, a 70.60% decline from fiscal 2024.
- 10x Genomics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $36.40M, a 53.81% decline from fiscal 2023.
- 10x Genomics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $78.80M, a 54.21% increase from fiscal 2022.
- 10x Genomics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $51.10M, a 59.54% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $10.70M 10-K · filed 2026-02-13 |
| 2024-12-31 | $36.40M 10-K · filed 2026-02-13 |
| 2023-12-31 | $78.80M 10-K · filed 2025-02-13 |
| 2022-12-31 | $51.10M 10-K · filed 2024-02-15 |
| 2021-12-31 | $126.30M 10-K · filed 2023-02-16 |
| 2020-12-31 | $120.40M 10-K · filed 2022-02-18 |
| 2019-12-31 | $10.80M 10-K · filed 2021-02-26 |
| 2018-12-31 | $19.30M 10-K · filed 2020-02-27 |